Loading briefing details...
Loading briefing details...
News Brief
By: PointLine Media Research & Editorial Team
Category:Business,Health,Industry,Lifestyle,Science & Environment
September 10, 2026
This regulatory approval validates the scientific trajectory of Redsenol-1 Plus, marking a crucial step in integrating rare ginsenosides into oncology supportive care. By refining protocols, the company enhances the viability of natural botanical interventions, potentially setting a new standard for managing chronic cancer-related fatigue through evidence-based clinical research.
Canada Royal Enoch Phytomedicine Ltd. has reached a significant milestone in its ongoing clinical research as Health Canada approved an updated protocol for the Redsenol-1 Plus Noble Ginsenoside Capsules trial. This investigational natural health product is specifically being evaluated for its efficacy in mitigating cancer-related fatigue (CRF), a debilitating condition that frequently impairs the quality of life for oncology patients undergoing treatments like chemotherapy and radiotherapy.
Since the study commenced in 2022, the research team has leveraged real-world clinical data to refine the trial's methodology and enhance participant access. This regulatory clearance allows the company to move forward with a modernized research framework, ensuring that the study continues to meet the highest standards of safety and scientific rigor while potentially expanding the cohort of eligible participants seeking supportive care solutions.
Redsenol-1 Plus, currently listed in the U.S. National Cancer Institute (NCI) Drug Dictionary, features a unique, proprietary blend of sixteen rare ginsenosides. By advancing this clinical investigation, Canada Royal Enoch Phytomedicine remains dedicated to unlocking the therapeutic potential of botanical formulations, aiming to provide evidence-based support for patients navigating the complex, long-term challenges associated with cancer recovery and daily functional health.